Navigation Links
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model
Date:3/8/2010

Talaris to leverage Lee's venture capital expertise with more than 55 portfolio therapeutics, medical device and healthcare services companies.

Hopkinton, MA (PRWEB) March 8, 2010 -- Talaris Advisors, LLC, today announced the appointment of Derek H. Lee to the role of Chief Financial and Corporate Development Officer. Mr. Lee comes to Talaris from SV Life Sciences (SVLS), a leading healthcare venture capital firm with capital commitments of approximately $1.5 billion. He was responsible for directing strategic financial and investment planning that incorporated market considerations into the operational performance and financing requirements of more than 55 portfolio therapeutics, medical device and healthcare services companies.

"We are entering a new phase of biotech and pharma investment today where success will be determined by a company's ability to make smart analytical decisions about its drug development candidates and terminate programs early and quickly when they miss key competitive and capital indicators,” commented Mark J. Pykett, Chief Executive Officer. “In this regard, Derek brings a strong investor perspective to our operations. His experience in aligning development with exit strategies and realizing optimal exits are a key component of Talaris’ value proposition. As our Chief Financial and Corporate Development Officer, Derek's ability to conduct quantitative and qualitative analyses, identify key risks and opportunities in complex financial and valuation models, and facilitate negotiations will give us the corporate vantage point our valued clients and investors need.”

Derek brings a decade's worth of expertise in ensuring some of the best management teams in the industry achieved their investment objectives. His background includes a range of experiences, from private and public financing strategies, to M&A transactions, partnerships and deal structuring. Lee has prior experience working with the Global Healthcare Group at UBS Warburg and with the Healthcare Investment Banking Group at Salomon Smith Barney. He received his BS Finance from Bentley College.

ABOUT TALARIS ADVISORS, LLC
Talaris Advisors works with biotech managers, companies and investors to optimize the use of capital and exit outcomes for drug development programs. Veteran team members, averaging 30 years of drug development experience, design and implement strategies that improve success rates, build multiple exit options and maximize investment returns for therapeutic drug assets. We align the commercial and regulatory requirements of drug candidates in development programs to reduce risk and time factors in pre-IND to Phase II proof-of-concept development, improving their odds for regulatory and commercial success. For investors, our integrated portfolio approach diversifies intrinsic investment risks. Members of the Talaris team have successfully completed more than 125 clinical studies and advanced more than 30 drug products through to the market. The company is headquartered in Hopkinton, Massachusetts. Please visit Talaris at www.talarisadvisors.com.

Media Contact:
Vicki Byatte
Talaris Advisors
Telephone: 508-497-2300 x 229    
Email: vbyatte(at)talarisadvisors(dot)com

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3692184.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
2. USHEALTH Career Agency Announces Americas Choice
3. Study: Choice between stroke-prevention procedures influenced by patient age
4. Nurtur Acquires ActivHealth and Wellness by Choice; Gains Exclusive Partnership with Duke University Center for Living
5. PCMA: Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans
6. New Online Store Makes Buying Cosmetics a Healthy Choice
7. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
8. Summit Medical Group Physician Named "Nurses Choice: Top Doctor"
9. Healthy Choice Shatters the Winter Mealtime Rut With 11 Delicious New Frozen Entrees
10. Morrisey Associates Partners With Total Living Choices (TLC) to Provide Software Value-Add to Customers
11. Security Choice Warns Against Dangers of Carbon Monoxide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Choice of Derek H. Lee as Chief Financial and Corporate Development Officer Strengthens Talaris Advisors' Portfolio Design Business Model 
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known ... for in a show called "Front Page". One of the forthcoming episodes examines mammogram ... rates have plummeted in large part due to early detection. Like any other disease, ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Entrepreneurial Company in the Dallas area” Tuesday evening at the 26th Annual SMU ... presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Findings from ... safety of CTL019, an investigational chimeric antigen receptor ... pediatric and young adult patients with B-cell acute ... an oral session at the 58th American Society ... 3, 4:00-5:30 p.m.). The global Phase II study ...
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical Laboratories, ... de la Compañía, el INSTI HIV Self Test , a los miembros ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
Breaking Medicine Technology: